Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is projected to see significant growth in Wakix sales, anticipated to increase from approximately $160 million in 2020 to over $700 million by 2024, driven by the drug's safety and convenience advantage. The company has a strong pipeline of orphan drug candidates in various stages of development, including pitolisant-GR, which aims to enhance patient adherence by removing the need for dose titration. Additionally, ongoing and upcoming registrational trials, combined with a robust balance sheet to fund research and development, position Harmony as a compelling growth story within the neurology sector.

Bears say

Harmony Biosciences Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock. The failure of the pivotal Phase 3 RECONNECT trial for ZYN002, attributed to a higher-than-expected placebo response, raises concerns about the viability of its drug pipeline and underscores potential hurdles in future clinical trials. Additionally, increasing competition in the sodium oxybate market and the possibility of slowed patient acquisition for WAKIX further complicate the company's growth prospects.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.